E7080 (Lenvatinib)
Catalog No. A10340
E7080 (Lenvatinib)是一种多激酶抑制剂,可同时抑制VEGFR2和VEGFR3激酶。
- Mai Nakahara, .et al. Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells, Biomed Rep, 2022, Aug 3;17(4):78 PMID: 36158319
- Paula Sagmeister, .et al. Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis, J Hepatocell Carcinoma, 2022, Jul 9;9:595-607 PMID: 35845819
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Keisuke Enomoto, .et al. Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models, Cancers (Basel), 2021, Feb 18;13(4):862 PMID: 33670725
- Jindal A, .et al. Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma, J Transl Sci, 2020, 7: 1-10
- Koide H, .et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1, Xenobiotica, 2018, Oct;48(10):1059-1071 PMID: 29034773
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
- Tomoko Ogawa-Morita, .et al. Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma, Int J Anal Chem, 2017, 2017: 2341876 PMID: 28680445
Catalog Num | A10340 |
---|---|
M. Wt | 426.9 |
Formula | C21H19ClN4O4 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 417716-92-8 |
Synonyms | E-7080 |
SMILES | COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl |
E7080 (Lenvatinib)是一种多激酶抑制剂,可同时抑制VEGFR2和VEGFR3激酶。
Targets
Target | Value |
---|---|
VEGFR2/KDR | IC50: 4.0nM |
VEGFR3/FLT4 | IC50: 5.2nM |
VEGFR1/FLT1 | IC50: 22nM |
PDGFRβ | IC50: 39nM |
FGFR1 | IC50: 46nM |
PDGFRα | IC50: 51nM |
Kit | IC50: 100nM |
EphB4 | IC50: >10μM |
IGF-1R | IC50: >10μM |
Insulin Receptor | IC50: >10μM |
Src | IC50: >10μM |
Akt1 | IC50: >10μM |
CDK4/CyclinD | IC50: >10μM |
PLK1 | IC50: >10μM |
FAK | IC50: >10μM |
PKCα | IC50: >10μM |
In vitro (25°C) | DMSO | Warmed: 35 mg/mL (81.99 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 0.5% methylcellulose | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 23.42 mL | 117.12 mL | 234.25 mL |
0.5 mM | 4.68 mL | 23.42 mL | 46.85 mL |
1 mM | 2.34 mL | 11.71 mL | 23.42 mL |
5 mM | 0.47 mL | 2.34 mL | 4.68 mL |
*The above data is based on the productmolecular weight 426.9. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.